Delivers doses from 15 to 60 units in a single injection.
For complete information, visit Sanofi
Soliqua 100/33 is formulated in a 3:1 ratio of insulin glargine U100: lixisenatide. Soliqua 100/33 is delivered in 1U increments of insulin glargine and 0.33mcg of lixisenatide. The top dose available in each Soliqua 100/33 pen is 60U (insulin glargine U100): 20mcg lixisenatide.
SOLIQUA 100/33 is a fixed-ratio combination of a long acting human insulin analog (insulin glargine U100) with a glucagon-like receptor agonist (GLP-1RA) (lixisenatide) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus administered 1 hour before the 1st meal of the day.
This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or healthcare provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit diabeteseducator.org.
ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.